Patent intelligence · US
US 9688726
Small molecule polypeptide for inhibiting inflammation
Small molecule polypeptide for inhibiting inflammation
Patent details — US 9688726
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 27, 2017
- Expiration
- Jun 22, 2037
- Applicant
- SHANGHAI FIRST PEOPLE'S HOSPITAL
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P31/00
Quick answer
US 9688726 (Small molecule polypeptide for inhibiting inflammation) is held by SHANGHAI FIRST PEOPLE'S HOSPITAL. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SHANGHAI FIRST PEOPLE'S HOSPITAL
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P31/00, A61P37/00
More from SHANGHAI FIRST PEOPLE'S HOSPITAL
Related pharmaceutical patents in our USPTO index.
-
US 12357666
Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof
granted -
US 12228572
Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
granted -
US 12220446
Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
granted -
US 12090156
Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
granted -
US 12076443
Preparation method of nanozyme composite-based hybrid hydrogel eye drop
granted -
US 12016950
Devices and methods for treating ear pain
granted -
US 11992555
Solid solution compositions and use in chronic inflammation
granted -
US 11980602
Cannabinoid prodrug compounds
granted
Frequently asked questions
What is US patent 9688726?
US 9688726 (Small molecule polypeptide for inhibiting inflammation) is held by SHANGHAI FIRST PEOPLE'S HOSPITAL. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9688726?
SHANGHAI FIRST PEOPLE'S HOSPITAL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 123 pharmaceutical patents for this assignee.
When does US 9688726 expire?
Our index shows an expiration date of Jun 22, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.